HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gladice Wallraven Selected Research

FANG vaccine

12/2021Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
8/2021Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
1/2021Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
12/2020Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
1/2017Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
12/2016Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
8/2016Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
3/2012Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gladice Wallraven Research Topics

Disease

10Neoplasms (Cancer)
01/2022 - 01/2011
6Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 12/2016
3Ewing Sarcoma (Sarcoma, Ewing)
01/2017 - 06/2015
1Colorectal Neoplasms (Colorectal Cancer)
10/2021
1Neoplasm Metastasis (Metastasis)
10/2021
1Liver Neoplasms (Liver Cancer)
01/2014
1Hepatocellular Carcinoma (Hepatoma)
01/2014
1Melanoma (Melanoma, Malignant)
01/2011

Drug/Important Bio-Agent (IBA)

8FANG vaccineIBA
12/2021 - 03/2012
4Small Interfering RNA (siRNA)IBA
01/2022 - 01/2014
4Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
10/2021 - 01/2011
3FurinIBA
01/2022 - 03/2012
3DNA (Deoxyribonucleic Acid)IBA
01/2017 - 08/2016
2VaccinesIBA
01/2022 - 01/2011
2Carboplatin (JM8)FDA LinkGeneric
12/2020 - 12/2016
2Paclitaxel (Taxol)FDA LinkGeneric
12/2020 - 12/2016
1atezolizumabIBA
01/2022
1antineoplaston A10 (A 10)IBA
01/2017
1Tubulin ModulatorsIBA
06/2015
1Interferon-gamma (Interferon, gamma)IBA
06/2015
1EnzymesIBA
06/2015
1Transforming Growth Factors (Transforming Growth Factor)IBA
03/2012
1Glycoproteins (Glycoprotein)IBA
01/2011
1AntigensIBA
01/2011
1Transforming Growth Factor beta (TGF-beta)IBA
01/2011

Therapy/Procedure

9Immunotherapy
12/2021 - 01/2014
3Drug Therapy (Chemotherapy)
10/2021 - 01/2017
3Intradermal Injections
12/2016 - 03/2012
2Therapeutics
01/2014 - 01/2011
1Neoadjuvant Therapy
12/2016